학술논문
Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guideline by American Society of Clinical Oncology/College of American Pathologists Will Reduce False-Positive Tests.
Document Type
Article
Source
Subject
*BREAST cancer diagnosis
*DUCTAL carcinoma
*ALGORITHMS
*CANCER patient medical care
*CELL receptors
*DIAGNOSTIC errors
*EPIDERMAL growth factor
*GENE expression
*IMMUNOHISTOCHEMISTRY
*MEDICAL protocols
*MEDICAL practice
*DECISION making in clinical medicine
*FLUORESCENCE in situ hybridization
*DIAGNOSIS
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0003-9985
Abstract
The authors discuss the publication about the update of human epidermal growth factor receptor 2 (HER2) testing guideline for breast cancer by the American Society of Clinical Oncology and the College of American Pathologists in the "Journal of Clinical Oncology." Topics discussed include the alternative D17S122 probe tested in 265 HER2-negative cases, the use of reflex tests to classify equivocal cases, and the evaluation criteria for cases with non-classical HER2 amplification.